Thyroxin

Dulbecco’s Modified Eagle’s Medium (DMEM), poly-D-lysine (PDL), putrescine, thyroxin, tri-iodothyroxine, progesterone, sodium selenite, papain, deoxyribonuclease l, bovine serum albumin (BSA) fraction V, and insulin were purchased from Sigma-Aldrich. L-glutamine, 0.25% trypsin-EDTA, and fetal bovine serum (FBS) were purchased from Invitrogen/Life Technologies. MEM was purchased from Gibco/Life Technologies. Holo-transferrin (human) was purchased from EMD Millipore. Trypsin inhibitor was purchased from Roche Life Science. FGF-basic and EGF were purchased from Peprotech. PDGF-AA was purchased from R&D Systems Inc.

Compound 1 (CITCO, (6-(4-chlorophenyl)imidazo [2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichloro-benzyl)oxime)),
rifampicin (rif), TCPOBOP, and PK11195 were obtained from Sigma-Aldrich
(St. Louis, Missouri, United States, now Merck), which is now known
as Merck (Darmstadt, Germany). Phenobarbital (Luminal 200 mg/mL injection)
was manufactured by Desitin Pharma spol. s.r.o. (Prague, Czech Republic).
Ligands for nuclear receptors (GW3965, thyroxin, obeticholic acid,
dexamethasone, fenofibrate, GW501516, rosiglitazone, 3-methylcholanthrene,
calcitriol, testosterone, and estradiol) were purchased from Sigma-Aldrich
(now Merck). The prototype ligands were used at 100 nM (dexamethasone,
calcitriol), 1 μM (thyroxin), or 10 μM concentrations.
The compounds were dissolved in DMSO, and the final concentration
of DMSO in the entire reaction mixture or cultivation media was 0.1%.